Identification of biomarkers that predict responsiveness to Benralizumab among severe asthma

Identification of biomarkers that predict responsiveness to Benralizumab among severe asthma - Biomarker for Benralizumab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041914

Enrollment

Registered

2020-09-28

Start date

2018-05-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient with severe asthma 2. Patient going to use Benralizumab 3. Patient using high dose ICS and other control agents

Exclusion criteria

Exclusion criteria: Patient whom the researchers think is not suitable for the study.

Design outcomes

Primary

Measure	Time frame
Relationships between a change in GETE and serum cytokine levels	—

Countries

Japan

Contacts

Public ContactMaho Suzukawa

National Hospital Organization Tokyo National Hospital Clinical Research Center

fueta-tky@umin.ac.jp042-491-2111

Outcome results